Pharma sees red as India allows Natco to produce patented Nexavar at 3% of Bayer's price
This article was originally published in Scrip
India has approved its first ever compulsory licence in the area of medicines for Bayer's anticancer Nexavar (sorafenib tosylate), allowing the domestic firm Natco Pharma, to self manufacture and sell a version of Nexavar for just over 3% of the price that Bayer sells the drug for in India.
You may also be interested in...
Nexavar compulsory license holder Natco Pharma is counted among the leading players in the Indian oncology market and now looks to be aiming for an encore in the hepatitis C segment. Natco vice chair and CEO Rajeev Nannapaneni talks to Scrip of the large patient numbers on HCV therapy and outlines a potential market "split" in certain rest of the world (RoW) territories with the arrival of Gilead's Epclusa.
Private assurances or not, the prickly debate around the use of compulsory licenses in India appears to have an ongoing subtext going by the transcript of statements by the US-India Business Council (USIBC) before the United States Trade Representative (USTR) at the 2016 Special 301 review public hearing.
Mylan gets approval in India for pretomanid as part of a combination regimen with bedaquiline and linezolid, providing new hope to patients with drug-resistant tuberculosis. Volume changes may provide opportunities to tweak prices.